Molina Healthcare Posts Q4 Loss

Molina Healthcare reported a Q4 net loss of $160 million ($3.15/share) versus net income of $251 million ($4.44/share) year‑ago; adjusted net loss was $140 million ($2.75/share) versus adjusted net income of $286 million ($5.05/share) last year. Quarterly revenue rose to $11.375 billion from $10.499 billion a year earlier. For fiscal 2026 the company guided to $44.5 billion in revenue, GAAP EPS of about $3.20 and adjusted EPS of about $5.00, signaling management expects a rebound despite the current quarter's earnings shortfall.

Analysis

Market structure: Molina’s Q4 adjusted loss (-$2.75/sh) and FY26 guidance (EPS $3.20, adj $5.00 on $44.5B revenue) signal near-term margin stress for Medicaid-focused managed care. Direct losers are small/mid-cap Medicaid specialists (MOH, smaller regional players) facing reserve and pricing pressure; winners are larger diversified MA/Commercial players (UNH, ELV, CNC) with better pricing power and broader risk pools. Credit markets may reprice smaller insurers—expect wider high‑yield and muni-insurer CDS spreads; equity/option IV on MOH should remain elevated for 1–3 months as guidance is digested.

Risk assessment: Tail risks include state rate cuts or non-renewal of Medicaid contracts, adverse reserve development >$500M, or an inspector general audit that could force additional reserves—each could drive >40% equity downside. Immediate (days) risk is a volatility spike and outflows; short-term (3–6 months) is guidance re‑forecast and state rate actions; long-term (12–24 months) depends on MA penetration and execution on cost controls. Hidden: MOH’s margin sensitivity to medical-loss-ratio changes and capitation timing; catalysts include state budget cycles (next 30–90 days) and MOH investor call commentary.

Trade implications: Tactical short bias on MOH is warranted short-term; consider options to limit capital at risk while capturing elevated IV. Relative-value: long Centene (CNC) or UNH vs short MOH to express quality dispersion across 6–12 months. Rotate capital away from concentrated Medicaid plays into large cap MA names and IG insurer debt to reduce credit beta.

Contrarian angles: Consensus may underweight MOH’s ability to recover via rate resets and Medicare/MA expansion—adj EPS guidance $5.00 implies recovery potential if execution holds, so a measured long on substantial pullback could pay off 12–18 months out. Market may overprice structural failure; historical parallels (insurer earnings misses 2015–2017 followed by rate resets) suggest 30–40% rebounds are possible if state rate actions are constructive. Unintended consequence of aggressive shorting: regulatory intervention or state contract support that compresses expected downside.

Key Decisions for Investors

• Establish a 2–3% portfolio short position in MOH (ticker MOH) with a 3–6 month horizon; set a hard stop-loss at +15% and a profit target of 30–40% downside if guidance revisions or reserve hits materialize.
• Initiate a 1.5–3% pair trade: long Centene (CNC) or Elevance (ELV) equal notional vs short MOH for 6–12 months to capture spread between diversified MA players and Medicaid specialists; tighten stops at 10% adverse move.
• Buy a limited-risk options hedge: 3-month MOH 15% OTM put spread (buy 15% OTM, sell 30% OTM) sized ~0.75–1% of portfolio to capture downside while financing premium; roll or widen if IV falls below historical mean within 60 days.
• Rotate 3–5% of exposure from small-cap Medicaid-focused names into UNH or ELV equity and 2–5y UNH investment-grade bonds for 12–24 months to reduce credit/operational risk and lock lower volatility earnings exposure.
• Monitor state Medicaid rate decisions and MOH reserve filings over the next 30–60 days; if ≥2 material states reduce rates or MOH files incremental reserves >$300M, increase short to 4–5% and add puts.